Bufei Yishen Formula (BYF) has been used for centuries in Asia to effectively treat patients with
chronic obstructive pulmonary disease (
COPD). This study established a
COPD animal model in rats, wherein three groups (control,
COPD, and BYF) were used to evaluate the mechanism(s) and curative effect of BYF. Pulmonary function and histomorphology demonstrated that BYF had an evident effect on
COPD. Gene microarray was then exploited to analyze the effects of BYF on
COPD. ClueGO analysis of differentially expressed genes indicated that BYF improved
COPD by regulating expression of
interleukins,
myosin filament assembly components, and mitochondrial electron transport-related molecules. Moreover, ELISA revealed that expression of several
interleukins (IL1 β ,
IL6,
IL8, and
IL10) was reduced in peripheral blood and bronchoalveolar lavage fluid by BYF treatment. It was concluded that BYF has
therapeutic effects on
COPD in rats through its effects on
interleukin expression and/or secretion. Furthermore, pharmacological or targeted expression of two differentially expressed genes, F2R and Sprik1, might be useful in novel
COPD therapies. This study provides the basis for mechanisms of BYF on
COPD and new therapeutic
drug targets.